ArticleNature communications2024
Protection against symptomatic dengue infection by neutralizing antibodies varies by infection history and infecting serotype.
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 50 citations in OpenAlex.
- Functional antibody responses and protection against symptomatic dengue.Communications medicine · 2026Review
- Dengue virus envelope epitope-specific antibodies are associated with protection from severe dengue.EMBO molecular medicine · 2026Article
- Acute-Phase Dengue Antibody Profiles in Pediatric Patients: Influence on Viremia and Disease Manifestations.Viruses · 2026Article
- Longitudinal antibody profiling after dengue reveals distinct dynamics by antibody specificity over 18 months.Nature communications · 2026Article
- Multiple, but not isolated, yellow fever virus-associated orthoflavivirus immune histories drive antibody-dependent enhancement of Zika and dengue viruses.medRxiv : the preprint server for health sciences · 2026Article
- Safety of a tetravalent live dengue virus vaccine in children responding to one serotype only.JCI insight · 2026Article
- Investigating antibody cross-reactivity and transmission dynamics of alphaviruses and flaviviruses using a multiplex serological assay.Nature communications · 2026Article
- Enhancing, controlling, and sterilizing dengue immunity and the development of broadly protective responses.medRxiv : the preprint server for health sciences · 2026Article
- Mathematical modeling of sequential Dengue-Zika infections: dynamic insights into antibody-dependent enhancement and neutralization effects.Scientific reports · 2026Article
- Application of Orthoflavivirus Pseudovirus Technology in Antiviral Research.International journal of molecular sciences · 2026Review
- Mapping immune responses to TAK-003 dengue vaccine: immunogenicity across the clinical development program.Frontiers in immunology · 2026Review
- Antiviral Strategies Against Dengue Virus: Recent Insights into Compounds Targeting Viral and Host Factors.Current topics in microbiology and immunology · 2026Review
- Virus-like Particles and Spectral Flow Cytometry for Identification of Dengue Virus-Specific B Cells in Mice and Humans.Viruses · 2025Article
- Dengue and severe dengue.Clinical microbiology reviews · 2025Review
- CD4Vaccines · 2025Article
- Chronic and reactivated dengue infection in an immunocompromised host: insights from a case report.Tropical medicine and health · 2025Article
- Acute Febrile Illness Associated with an Emerging Dengue 4 GIIb Variant Causing Epidemic in León, Nicaragua 2022.Viruses · 2025Article
- Efficacy, public health impact and optimal use of the Takeda dengue vaccine.Nature medicine · 2025Article
- Anti-Dengue Virus Antibody Avidity Correlates With Protection Against Symptomatic Dengue Virus Infection.The Journal of infectious diseases · 2025Article
- Protective envelope dimer epitope-like antibodies are elicited against dengue virus in children after infection and vaccination.Science translational medicine · 2025Article
Corrections and comments
- Update of
Authors and funding
13 authors at 8 institutions in 3 countries.
Funding
Abstract
Dengue viruses (DENV1-4) are the most prevalent arboviruses in humans and a major public health concern. Understanding immune mechanisms that modulate DENV infection outcome is critical for vaccine development. Neutralizing antibodies (nAbs) are an essential component of the protective immune response, yet their measurement often relies on a single cellular substrate and partially mature virions, which does not capture the full breadth of neutralizing activity and may lead to biased estimations of nAb potency. Here, we analyze 125 samples collected after one or more DENV infections but prior to subsequent symptomatic or inapparent DENV1, DENV2, or DENV3 infections from a long-standing pediatric cohort study in Nicaragua. By assessing nAb responses using Vero cells with or without DC-SIGN and with mature or partially mature virions, we find that nAb potency and the protective NT50 cutoff are greatly influenced by cell substrate and virion maturation state. Additionally, the correlation between nAb titer and protection from disease depends on prior infection history and infecting serotype. Finally, we uncover variations in nAb composition that contribute to protection from symptomatic infection differently after primary and secondary prior infection. These findings have important implications for identifying antibody correlates of protection for vaccines and natural infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.